{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:25:41Z","timestamp":1762521941591},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["diabetesresearchclinicalpractice.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.diabres.2016.09.016","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T09:51:21Z","timestamp":1475229081000},"page":"204-214","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME"],"prefix":"10.1016","volume":"121","author":[{"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2016.09.016_b0005","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0010","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(14)61212-5","article-title":"Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data","volume":"384","author":"Blood Pressure Lowering Treatment Trialists C","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0015","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0020","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2016.09.016_b0025","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0030","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0035","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0040","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"Ryden","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2016.09.016_b0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11906-015-0561-1","article-title":"Benefit of blood pressure control in diabetic patients","volume":"17","author":"Kintscher","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.diabres.2016.09.016_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008277.pub2","article-title":"Blood pressure targets for hypertension in people with diabetes mellitus","volume":"10","author":"Arguedas","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.diabres.2016.09.016_b0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1161\/HYPERTENSIONAHA.115.06735","article-title":"SPRINT, or false start, toward a lower universal treated blood pressure target in hypertension","volume":"67","author":"Esler","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.diabres.2016.09.016_b0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jch.12638","article-title":"Diabetes and hypertension: a comparative review of current guidelines","volume":"18","author":"Cryer","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.diabres.2016.09.016_b0075","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.diabet.2014.03.004","article-title":"Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal","volume":"40","author":"Scheen","year":"2014","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0080","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2016.09.016_b0085","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.clinthera.2016.04.037","article-title":"EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus","volume":"38","author":"Schernthaner","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2016.09.016_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.clinthera.2016.03.035","article-title":"Clinical implications of cardiovascular outcome trials in type 2 diabetes: from DCCT to EMPA-REG","volume":"38","author":"Ryden","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2016.09.016_b0095","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrcardio.2012.183","article-title":"Cardiovascular effects of gliptins","volume":"10","author":"Scheen","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabres.2016.09.016_b0100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","article-title":"Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes","volume":"14","author":"Scheen","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.diabres.2016.09.016_b0105","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.diabres.2016.09.016_b0120","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.diabres.2016.09.016_b0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2016.02.134","article-title":"Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies","volume":"212","author":"Ghosh","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabres.2016.09.016_b0130","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jash.2014.11.001","article-title":"SGLT2 inhibitors: their potential reduction in blood pressure","volume":"9","author":"Maliha","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0140","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1097\/HJH.0000000000000719","article-title":"Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?","volume":"33","author":"Imprialos","year":"2015","journal-title":"J Hypertens"},{"issue":"262\u2013275","key":"10.1016\/j.diabres.2016.09.016_b0145","first-page":"e9","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis","volume":"8","author":"Baker","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0150","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2016.09.016_b0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.diabet.2015.12.005","article-title":"Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2015.10.013","article-title":"The EMPA-REG study: What has it told us? A diabetologist\u2019s perspective","volume":"30","author":"DeFronzo","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2016.09.016_b0165","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2016.09.016_b0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jash.2016.01.009","article-title":"Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis","volume":"10","author":"Kimura","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2015.07.072","article-title":"Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure","volume":"201","author":"Takeuchi","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabres.2016.09.016_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdiacomp.2015.10.012","article-title":"EMPA-REG - the \u201cdiuretic hypothesis\u201d","volume":"30","author":"McMurray","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2016.09.016_b0185","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2016.09.016_b0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2016.05.006","article-title":"Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: comparison with classic diuretics","volume":"42","author":"Scheen","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/2230-8210.176361","article-title":"Empagliflozin: not just a glorified diuretic","volume":"20","author":"John","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0200","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.diabres.2016.09.016_b0210","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/jch.12425","article-title":"Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus","volume":"16","author":"Weir","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.diabres.2016.09.016_b0215","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0220","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2016.09.016_b0225","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sjostrom","year":"2015","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.diabres.2016.09.016_b0230","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2337\/dc14-1096","article-title":"Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension","volume":"38","author":"Tikkanen","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.09.016_b0235","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/dom.12486","article-title":"Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension","volume":"17","author":"Amin","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0240","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/hr.2016.1","article-title":"Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes","volume":"39","author":"Tamura","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1016\/j.diabres.2016.09.016_b0245","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0250","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2016.09.016_b0255","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.09.016_b0260","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diabres.2016.09.016_b0265","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.diabres.2016.09.016_b0270","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2016.09.016_b0275","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijcard.2016.01.197","article-title":"Blood pressure lowering and stroke events in type 2 diabetes: a network meta-analysis of randomized controlled trials","volume":"208","author":"Xie","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabres.2016.09.016_b0280","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstrom","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.diabres.2016.09.016_b0285","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.09.016_b0290","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/jch.12816","article-title":"Cardiovascular outcomes according to systolic blood pressure in patients with and without diabetes: an ACCOMPLISH substudy","volume":"18","author":"Weber","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.diabres.2016.09.016_b0300","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0305","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0310","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2016.09.016_b0315","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-pressure lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.09.016_b0320","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.diabres.2016.09.016_b0325","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1161\/CIRCULATIONAHA.105.544031","article-title":"Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-lowering treatment to prevent heart attack trial","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"issue":"Suppl. 2","key":"10.1016\/j.diabres.2016.09.016_b0330","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.2337\/dc11-s246","article-title":"Diuretic treatment of hypertension","volume":"34","author":"Grossman","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.09.016_b0335","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5414\/CPP47434","article-title":"Target blood pressure attainment in diabetic hypertensive patients: need for more diuretics?","volume":"47","author":"Sweileh","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.diabres.2016.09.016_b0340","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/ajh\/hpv050","article-title":"Cardioprotective effect of thiazide-like diuretics: a meta-analysis","volume":"28","author":"Chen","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0345","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.114.05122","article-title":"Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis","volume":"65","author":"Olde Engberink","year":"2015","journal-title":"Hypertension"},{"issue":"Suppl. 2","key":"10.1016\/j.diabres.2016.09.016_b0350","first-page":"B65","article-title":"Efficacy of diuretics and beta-blockers in diabetic hypertensive patients. Results from a meta-analysis. The INDANA Steering Committee","volume":"23","author":"Lievre","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.09.016_b0355","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jdiacomp.2016.04.020","article-title":"Classes of antihypertensive agents and mortality in hypertensive patients with type 2 diabetes-Network meta-analysis of randomized trials","volume":"30","author":"Remonti","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.diabres.2016.09.016_b0360","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/jhh.2015.119","article-title":"Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis","volume":"30","author":"Takahashi","year":"2016","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.diabres.2016.09.016_b0365","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12872-016-0198-2","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.diabres.2016.09.016_b0370","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","article-title":"Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis","volume":"177","author":"Pelliccia","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabres.2016.09.016_b0375","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2016.09.016_b0380","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","author":"Monami","year":"2016","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2016.09.016_b0385","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S2213-8587(15)00424-6","article-title":"Understanding EMPA-REG OUTCOME","volume":"3","author":"Muskiet","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabres.2016.09.016_b0390","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716305228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716305228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:51:24Z","timestamp":1568422284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716305228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":78,"alternative-id":["S0168822716305228"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.09.016","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}